168 Results for "

CD3 T cell

" in MedChemExpress (MCE) Product Catalog:
Products (168)

168 Results for "CD3 T cell" in MCE Product Catalog:

Cat. No.: HY-P991028
CAS No.: 2892667-02-4
Synonyms: AZD0486; TNB-486

Research Areas:  

Cancer

Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .
loading...
    loading...
Cat. No.: HY-P990864

Target:  

CD3

Research Areas:  

Inflammation/Immunology

Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human CD3. Anti-CD3 Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease .
loading...
    loading...
Cat. No.: HY-P99517
CAS No.: 2411871-58-2
Synonyms: JNJ-63898081; JNJ-081

Target:  

CD3 PSMA

Research Areas:  

Cancer

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
loading...
    loading...
Cat. No.: HY-P99038
CAS No.: 1801338-64-6
Synonyms: REGN1979

Target:  

CD20 CD3

Research Areas:  

Cancer

Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
loading...
    loading...
Cat. No.: HY-P990717
CAS No.: 2736407-54-6
Synonyms: IMC-F106C

Target:  

CD3

Research Areas:  

Cancer

Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3 + T cells to kill PRAME + tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P99948
CAS No.: 2329692-74-0
Synonyms: AMG-596

Target:  

EGFR CD3

Research Areas:  

Neurological Disease Cancer

Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .
loading...
    loading...
Cat. No.: HY-P99152
CAS No.: 140608-64-6
Synonyms: Muromanab-CD3

Research Areas:  

Inflammation/Immunology Cancer

Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
loading...
    loading...
Cat. No.: HY-P991731
Synonyms: ZG006
Target:  

CD3 Notch

Research Areas:  

Neurological Disease Cancer

Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .
loading...
    loading...
Cat. No.: HY-P990980
CAS No.: 2919209-65-5
Synonyms: CND-106; EMB-06
Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .
loading...
    loading...
Cat. No.: HY-P99623
CAS No.: 1664355-28-5
Synonyms: MGD006; S80880

Target:  

CD3

Research Areas:  

Cancer

Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-P990925
CAS No.: 2885203-43-8
Synonyms: BLYG8824A; RG6286
Target:  

CD3

Research Areas:  

Inflammation/Immunology

Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and CD3. Linclatamig can bind to LY6G6D and CD3-positive T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in colorectal cancer research .
loading...
    loading...
Cat. No.: HY-P99430
CAS No.: 2296827-07-9
Synonyms: EM901; CC-93269

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P9989
CAS No.: 2408319-25-3
Synonyms: REGN5458

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .
loading...
    loading...
Cat. No.: HY-P990981
CAS No.: 2930861-48-4
Synonyms: ALPS-12; RG-6524; RO 7616789

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC) .
loading...
    loading...
Cat. No.: HY-P99910
CAS No.: 1679391-73-1
Synonyms: AMG-330
Research Areas:  

Cancer

Eluvixtamab (AMG-330) is a bispecific T-cell engager (BiTE) antibody targeting CD33 and CD3, with a Kd of 5.1 nM and 8 nM for human and cynomolgus monkey CD3, respectively, and a Kd of 8 nM and 8.6 nM for human and cynomolgus monkey CD33, respectively. Eluvixtamab links T cells to CD33-expressing acute myeloid leukemia (AML) cells, triggers T-cell activation, and induces inflammatory adaptive immune escape characterized by PD-L1 upregulation in AML cells. Eluvixtamab is applicable to research related to acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-P991526
CAS No.: 2933295-42-0
Target:  

CD3

Research Areas:  

Cancer

M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and CD3 on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .
loading...
    loading...
Cat. No.: HY-131183
CAS No.: 2447066-37-5
Purity:  99.52%
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .
loading...
    loading...
Cat. No.: HY-P99523
CAS No.: 2413453-53-7
Synonyms: AMG 199

Target:  

CD3

Research Areas:  

Cancer

Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and CD3. Vepsitamab directs CD3-positive cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .
loading...
    loading...
Cat. No.: HY-P99390
CAS No.: 2044679-53-8
Synonyms: MCLA 117
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
loading...
    loading...
Cat. No.: HY-P990785
CAS No.: 2490552-52-6
Synonyms: ABBV-383; TNB 383B

Target:  

CD3

Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
loading...
    loading...